Leo Pharma's US sales organization waited 8 months on approval: "It has had an economic impact"

Since spring, 133 Leo Pharma sales representatives have been at the ready to send tralokinumab to the US market. The wait has been spent on selling other products and learning from the eczema drug's launches in Europe. On Tuesday, the US approval finally arrived.

While Becki Morison, executive vice president responsible for Global Therapeutic & Value Strategy at Leo Pharma, is disappointed over the 8-month delay of tralokinumab, the wait has also had some benefits | Photo: Leo Pharma/PR

When the US Food and Drug Administration (FDA) approved of Leo Pharma's drug, tralokinumab, as a treatment for atopic dermatitis, the Danish firm's entire US-based sales organization was ready to push the launch button. 

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs